We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemours (CC) to Divest Glycolic Acid Business to PureTech
Read MoreHide Full Article
The Chemours Company (CC - Free Report) agreed to sell its Glycolic Acid business to PureTech Scientific Inc. for $137 million in cash. PureTech Scientific is a company founded and backed by Iron Path Capital, a private equity firm focused on lower-middle market investments in the specialty industrial and healthcare sectors.
PureTech Scientific is positioning itself to become a leader in organic synthesis of ultra-high purity alpha hydroxy acids for the Life Sciences and Specialty Chemical industries with this acquisition. Subject to regulatory clearances and other normal closing conditions, the transaction is scheduled to close by the third quarter of 2023.
Chemours' Glycolic Acid portfolio contains technical and cosmetic grades that can be used in a variety of applications. As ardent stewards of these brands, the company believes that the portfolio complements PureTech Scientific's growth strategy, which is reflected in the terms of the agreement.
Shares of Chemours have lost 20.2% over the past year compared with the 8.5% decline of its industry.
Image Source: Zacks Investment Research
In April, the company reiterated its guidance for adjusted EBITDA and free cash flow for 2023. It anticipates adjusted EBITDA for 2023 to be between $1.20 billion and $1.30 billion. It also expects free cash flow of more than $350 million, including about $400 million in capital expenditures.
The Zacks Consensus Estimate for Koppers’ current-year earnings is currently pegged at $4.40, implying year-over-year growth of 6.3%. It has a trailing four-quarter earnings surprise of 13.64%, on average. KOP has gained 12% in a year.
The Zacks Consensus Estimate for Gold Fields’ current-year earnings has been revised 23.5% upward in the past 60 days. The consensus estimate for current-year earnings for GFI is currently pegged at $1.05, indicating year-over-year growth of 8.3%. The company’s shares have gained 63.8% in the past year.
The Zacks Consensus Estimate for Linde’s current-year earnings has been revised 3.8% upward in the past 60 days. LIN beat the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 6.9%, on average. The company’s shares have gained 7.2% in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Chemours (CC) to Divest Glycolic Acid Business to PureTech
The Chemours Company (CC - Free Report) agreed to sell its Glycolic Acid business to PureTech Scientific Inc. for $137 million in cash. PureTech Scientific is a company founded and backed by Iron Path Capital, a private equity firm focused on lower-middle market investments in the specialty industrial and healthcare sectors.
PureTech Scientific is positioning itself to become a leader in organic synthesis of ultra-high purity alpha hydroxy acids for the Life Sciences and Specialty Chemical industries with this acquisition. Subject to regulatory clearances and other normal closing conditions, the transaction is scheduled to close by the third quarter of 2023.
Chemours' Glycolic Acid portfolio contains technical and cosmetic grades that can be used in a variety of applications. As ardent stewards of these brands, the company believes that the portfolio complements PureTech Scientific's growth strategy, which is reflected in the terms of the agreement.
Shares of Chemours have lost 20.2% over the past year compared with the 8.5% decline of its industry.
Image Source: Zacks Investment Research
In April, the company reiterated its guidance for adjusted EBITDA and free cash flow for 2023. It anticipates adjusted EBITDA for 2023 to be between $1.20 billion and $1.30 billion. It also expects free cash flow of more than $350 million, including about $400 million in capital expenditures.
The Chemours Company Price and Consensus
The Chemours Company price-consensus-chart | The Chemours Company Quote
Zacks Rank & Key Picks
Chemours currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks to consider in the basic materials space include Koppers Holdings Inc. (KOP - Free Report) , Gold Fields Limited (GFI - Free Report) and Linde plc (LIN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Koppers’ current-year earnings is currently pegged at $4.40, implying year-over-year growth of 6.3%. It has a trailing four-quarter earnings surprise of 13.64%, on average. KOP has gained 12% in a year.
The Zacks Consensus Estimate for Gold Fields’ current-year earnings has been revised 23.5% upward in the past 60 days. The consensus estimate for current-year earnings for GFI is currently pegged at $1.05, indicating year-over-year growth of 8.3%. The company’s shares have gained 63.8% in the past year.
The Zacks Consensus Estimate for Linde’s current-year earnings has been revised 3.8% upward in the past 60 days. LIN beat the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 6.9%, on average. The company’s shares have gained 7.2% in the past year.